a CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde , Gandra PRD , Portugal.
b UCIBIO- REQUIMTE, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy University of Porto , Porto , Portugal.
J Dermatolog Treat. 2019 Nov;30(7):659-663. doi: 10.1080/09546634.2018.1544410. Epub 2018 Dec 2.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (PSO-TOPAP) and was applied to a total of seventy-nine patients, members of the Portuguese Association of Psoriasis (PSOPortugal) or outpatients of a dermatology unit of a central hospital. Overall, attributes belonging to the formulation and application domains were greatly valued over attributes related to the container. Only a small number of patient preferences was influenced by age, gender, duration of the disease and age at first diagnosis. Our findings need to be verified in larger and more diverse patient samples before generalization can be made. The insight obtained in this work can provide guidance to pharmaceutical drug product design and has also the potential to improve patient care through the acknowledgment of patient preferences in clinical practice.
在开具局部治疗药物时，应考虑患者的偏好，以提高患者的依从性并改善临床结果。本研究旨在确定患者眼中治疗银屑病的局部药物最重要的属性，并探讨这些偏好的社会人口统计学和临床决定因素。我们开发了一种评估用于治疗银屑病的局部药物特定属性相关性的问卷（PSO-TOPAP），并对 79 名患者进行了调查，这些患者是葡萄牙银屑病协会（PSOPortugal）的成员或一家中心医院皮肤科的门诊病人。总体而言，制剂和应用领域的属性比与容器相关的属性更受重视。只有少数患者的偏好受到年龄、性别、疾病持续时间和首次诊断年龄的影响。在推广之前，我们需要在更大和更多样化的患者样本中验证这些发现。这项工作获得的见解可以为药物产品设计提供指导，并通过在临床实践中承认患者的偏好，有可能改善患者的护理。
